Uterine cancers are the most common gynaecological cancer in Australia, yet they're also among the most underfunded. Between 2003 and 2020, uterine cancers received just $18 million in research funding. Breast cancer received $442 million over the same period. Women with advanced uterine cancers have 11.5x fewer treatment options than women with metastatic breast cancer. Not because the need isn't there. Because the investment hasn't been. This is what EDEN was designed to change. Learn more about the EDEN initiative: anzgog.org.au/research/eden/ #UterineCancerAwarenessMonth #SavingLives #UterineCancer

Uterine cancers are no longer just a disease of older women. Incidence among Australian women aged 25-44 is projected to rise by approximately 60% by 2035. And the impact isn't felt equally. Aboriginal and Torres Strait Islander women, women in regional and remote communities, and women from lower socioeconomic backgrounds all face significantly higher rates of diagnosis and death. A woman from a low socioeconomic background is 1.7 times more likely to die from uterine cancer than a woman from the wealthiest background. This month, we're talking about why uterine cancers affect some women more than others, and what needs to change. 🎧 On the Down Low Season 2 is exploring these questions in depth. Ep 2 looks at surgery and fertility considerations for younger women facing a diagnosis, and Ep 3 digs into the research, the treatment gaps, and the rising incidence data behind these numbers. Listen now: anzgog.org.au/on-the-down-lo… #UterineCancerAwarenessMonth #AdvancingResearchSavingLives @canceraustralia

Ella was diagnosed with endometrial cancer at 31. She had to fight to be taken seriously. Surgery worked, but placed her into menopause and took away her choice to have children. Women aged 35-44 are facing a projected 68% rise in incidence by 2035. This is not a disease of older women anymore. Donate by June 30 to fund research that changes outcomes: 🔗 womencan.org.au/appeal #UterineCancerAwarenessMonth #AdvancingResearchSavingLives @CancerAustralia

A powerful and important story from @ABC Health today shines a national spotlight on one of Australia’s most urgent and under-recognised cancer challenges: uterine cancers. Incidence has more than doubled over the past 25 years, making uterine cancers Australia’s fastest-rising women’s cancer. Yet awareness remains critically low, with most Australians unaware of the disease, its symptoms or risk factors. Thank you to ABC Health journalist @LaurenRoberts for her thoughtful reporting, and to Simone Crerar’s family for courageously sharing their story to help raise awareness and encourage earlier diagnosis. As highlighted by ANZGOG Chair Professor Clare Scott AM, greater awareness, earlier recognition of symptoms, and research investment are essential if we are to improve outcomes for women and reduce the growing burden of this disease. Read the ABC story: abc.net.au/news/health/2026-… #UterineCancer #UterineCancerAwarenessMonth #GynaecologicalCancer #CancerResearch #WomensHealth #ANZGOG

🎙️ It's Uterine Cancer Awareness Month — and there's no better time to tune in. Last year, On the Down Low: Speaking Up About Gynaecological Cancers returned with a powerful new season on uterine cancers (including endometrial cancer). Often unknown, deeply underfunded, and critically under-researched, uterine cancers are the most commonly diagnosed gynaecological cancer in Australia. Over the past 20 years, incidence has doubled in Australia and nearly tripled in New Zealand, with diagnoses particularly increasing among women aged 30–50, highlighting an urgent need for awareness, education, and investment. Across six episodes, you’ll hear from: 🔸 Advocates living with and beyond cancer 🔸 Leading clinicians and researchers from ANZGOG 🔸 Stories of impact, inequity, and hope Available on your favourite podcasting platforms. @CancerAustralia #UCAM #OnTheDownLowPodcast #UterineCancer #EndometrialCancer

Dr @g_auyeung and Prof @LindaMileshkin were at #ASCO26 in Chicago this week presenting the latest findings from IGNITE-Cerala, ANZGOG's Phase II investigator-initiated trial targeting recurrent high-grade serous ovarian cancer. IGNITE was conceived from preclinical research by Prof David Bowtell at @PeterMacCC, investigating novel approaches to targeting Cyclin E1, a protein that drives the growth of a subset of high-grade serous ovarian cancers. This marks the third time IGNITE has been presented on the world stage at ASCO 👏 #AdvancingResearchSavingLives

June is Uterine Cancer Awareness Month, and the picture across Australia and Aotearoa New Zealand cannot be ignored. Uterine cancers are the most common and fastest rising gynaecological cancers in Australia and Aotearoa New Zealand. And most women have never heard of it. Around 12 women across both countries will hear those words today. More than two will lose their lives. Yet 94% of women report they were unaware of uterine cancer. It is unknown, underfunded, and unsupported. Uterine cancers are the poorest funded cancer in terms of research funding, both in absolute terms and in terms of disease burden. That has to change. Our State of the Nation report sets out what we know and what must be done. Read it here: anzgog.org.au/state-of-the-n… @CancerAustralia #UCAM #UterineCancer #EndometrialCancer #AdvancingResearchSavingLives

This National Reconciliation Week, ANZGOG is proud to stand #AllIn. This year's theme is a call for all Australians to commit to reconciliation not as a moment, but as an everyday practice, one that belongs to every one of us, in every sector and every community. For ANZGOG, being All In means looking honestly at where women's cancer research and care is falling short and committing to do better. Aboriginal and Torres Strait Islander women are 3.4 times more likely to die from cervical cancer than non-Indigenous women. They are 1.2 times more likely to be diagnosed with, and to die from, uterine cancers. They continue to face barriers to culturally safe care, higher rates of late diagnosis, and remain under-represented in clinical trials. These disparities are not inevitable. Closing them requires genuine, ongoing partnership with Aboriginal and Torres Strait Islander women, communities and organisations and an unwavering commitment from the research sector to ensure every woman is included in the evidence that shapes her care. We are committed to playing our part. Not just this week, but every week. We acknowledge the Traditional Custodians of the lands across Australia on which we live, learn and work, and pay our respects to Elders past, present and emerging. #NRW2026 #AllIn #AdvancingResearchSavingLives @RecAustralia

Women are losing their lives because a common cancer has been ignored for too long. Ella was 31 when she was diagnosed. She'd never heard of it, even with a master's degree in health science. She had to Google it. Her cancer changed her life in ways she's still coming to terms with. But she's sharing her story so other women don't have to go through the same thing. Your tax-deductible donation to WomenCan before 30 June can fund research that saves lives like Ella's 💜 Donate today: womencan.org.au/appeal #SavingLives #EndometrialCancer #GynaecologicalCancer

Every breakthrough in gynaecological cancer care began with a clinical trial. Today is International Clinical Trials Day, and there's no better time to reflect on the progress we've made in gynaecological oncology. 50 trials. More than 4,500 patients entered. 1,650 members. 82 hospitals. 26 years of advancing research, saving lives. Behind every one of those numbers is a woman who said yes to a trial, a clinician who championed access, a researcher who refused to accept the status quo, and a donor who made the work possible. Clinical trials are how today's research becomes tomorrow's standard of care. For women with gynaecological cancer, it can be the difference between a limited option and a life-changing one. We're grateful to everyone who has been part of that work across 26 years. There is still so much more to do. #InternationalClinicalTrialsDay #AdvancingResearchSavingLives #ClinicalTrials #GynaecologicalCancer

Behind every clinical trial, every research priority, and every medical student who learns to recognise the signs of gynaecological cancer, there are volunteers. This National Volunteers Week, we want to acknowledge the incredible community members who power our Community Engagement Program (CEP). Completely volunteer-run, the CEP works across three pillars: Education, Research, and Advocacy. Each one reflects something we deeply believe: that the voices of women with lived experience belong at the centre of this work 💜 One of the most powerful expressions of that is Survivors Teaching Students, where CEP volunteers bring their lived experience directly into medical classrooms, changing the way future clinicians see and understand gynaecological cancer. We're actively looking for new volunteers in Tasmania and Western Australia to join the program. Could that be you? 👉 Learn more: anzgog.org.au/community-volu… #NationalVolunteersWeek #SurvivorsTeachingStudents #GynaecologicalCancer #AdvancingResearchSavingLives

Representatives from the 33 member groups of the Gynecologic Cancer Intergroup, including Australia New Zealand Gynaecological Oncology Group, recently came together in Toronto, Canada, for the 7th @GCIG Trials Ovarian Cancer Consensus Conference. The conference brought together global leaders in ovarian cancer research to help shape the next generation of international clinical trials, with key discussions focused on global access, patient-centred care, equity and inclusivity, pragmatic trial designs, and the integration of translational research. Professor @ @PaulCohen, Chair of ANZGOG’s Research Advisory Committee, said: “Recent years have seen many pivotal studies and new developments in ovarian cancer therapy, and the Toronto meeting featured in-depth discussion on how to incorporate these advances into the design, development and execution of the next generation of ovarian cancer clinical trials.” ANZGOG is proud to contribute to these important international collaborations, helping ensure women across Australia, New Zealand, and around the world benefit from continued advances in gynaecological cancer research and care. Thankyou to GCIG Trials and everyone involved. Photo: ANZGOG contingent left @JohnAndr , , Paul Cohen, Alison Brand AM, and Chee Lee. #ANZGOG #CancerResearch #InternationalCollaboration #GCIC

The much-needed increase to the Medical Research Future Fund announced in the Federal Budget is a critical first step for Australia’s health and research future. But for women with gynaecological cancers, the wait continues. Every day, 19 women are diagnosed. More than six will lose their lives. And for many women’s cancers, survival outcomes haven’t changed in decades. The Australia New Zealand Gynaecological Oncology Group (ANZGOG), the @ocrf , and @OvarianCancerOz Cancer Australia are united in calling for this funding to translate into meaningful action for gynaecological cancers. We will continue to work with the Government to ensure that the longstanding gaps across prevention, early diagnosis, treatment, clinical trials, survivorship, and supportive care are addressed urgently. This is a moment of opportunity — and responsibility. Read our joint statement: anzgog.org.au/federal-budget… #GynaecologicalCancer #WomensHealth #MedicalResearch #MRFF #HealthEquity #Strongertogether @RobinPenty @Jamie Snashall @MP David Pocock @RebeccaWhite @AndyGargett

⏰ Last chance - earlybird pricing closes tomorrow. Sign up today for the ANZGOG | WomenCan Fiordland Trek 2027 and save $150 on your registration fee. After 14 May, standard pricing applies. Four days trekking through one of the world's most breathtaking landscapes, raising vital funds for gynaecological cancer research. An experience you'll never forget, for a cause that truly matters. 🔗 Register today: hubs.li/Q048q1180

Each year, ANZGOG's Annual Scientific Meeting brings together leading experts from across Australia, New Zealand and the international gynaecologic oncology community to share knowledge, exchange ideas and strengthen collaboration 🌏 At this year's meeting, we were pleased to welcome three keynote speakers travelling from the USA and Malaysia: 🇺🇸🎙️ @DrKatyMoore, College of Allied Health - @UofOklahoma Health Sciences Center The Next Era of Ovarian Cancer Therapy: Precision, Payloads & Pathways 🇺🇸🎙️ Dr William Small, @LoyolaChicago Optimising Oncology: The Intersection of Oncology, Academic Trials & International Collaboration 🇲🇾🎙️ Professor Yin Ling Woo, @uni_malaya The Reality of Cervical Cancer Elimination: Making Research Relevant We extend our sincere thanks to @DrKatyMoore, Dr William Small and Professor Yin Ling Woo for their significant contributions to the 2026 ASM. Their participation supported valuable discussion and shared learning across the meeting. #ANZGOG2026ASM #GynaecologicalCancer #AdvancingResearchSavingLives

🌏 On World Ovarian Cancer Day 2026, an important new ovarian cancer clinical study has been announced, bringing new hope for women facing one of the most challenging forms of the disease. The PRROSE trial is a new investigator-initiated clinical study evaluating narmafotinib in combination with standard-of-care chemotherapy for women with high-grade serous ovarian cancer (HGSOC) who have not responded adequately to initial platinum-based chemotherapy prior to surgery, a group with limited treatment options and significant unmet clinical need. Approximately one in five women with ovarian cancer do not respond sufficiently to first-line chemotherapy, limiting surgical options and contributing to poorer outcomes. This study aims to address this significant unmet need by evaluating the safety of this treatment combination and exploring whether it may improve eligibility for successful surgery. Developed in collaboration with Amplia Therapeutics, the study is led by Dr Gwo Yaw Ho and sponsored and coordinated through ANZGOG’s international clinical trials network, to evaluate the safety of narmafotinib, in combination with carboplatin and paclitaxel chemotherapy. Commenting on the announcement, Dr Gwo Yaw Ho said: “This study reflects the strength of ANZGOG’s collaborative clinical trials network and its ability to bring together leading clinical investigators to address areas of high unmet need in gynaecological cancers.” On World Ovarian Cancer Day, this announcement reinforces ANZGOG’s commitment to advancing research that translates scientific innovation into better outcomes for women. #WorldOvarianCancerDay #WOCD2026 #OvarianCancer #CancerResearch #ANZGOG #NoWomanLeftBehind

Honouring Legacy, Inspiring the Future 💥 Celebrating 25 years of the Australian Ovarian Cancer Study A special moment at the #ANZGOG2026ASM Conference Dinner was the recognition of a significant milestone in ovarian cancer research, the 25-year legacy of the Australian Ovarian Cancer Study (AOCS). The largest and one of the most influential molecular epidemiological studies of ovarian cancer globally, AOCS has played a critical role in advancing understanding of the disease. Since its inception, the study has been closely connected with the ANZGOG community, with many members contributing over its 25-year journey. Professor Michael Friedlander AM, ANZGOG Co-Founder and inaugural Chair, invited both Professor David Bowtell and @DrLizChristie to the stage to mark this occasion and reflect on the extraordinary contribution of the AOCS team. Their leadership, alongside the collective efforts of researchers, clinicians and collaborators, has helped shape a body of work that continues to inform research and improve outcomes. This milestone serves as a powerful reminder of what can be achieved through long-term collaboration, shared purpose, and sustained investment in research. #AdvancingResearchSavingLives

Gynaecological cancers in Australia: a hidden crisis for women A powerful new article published in the Medical Journal of Australia, Insight authored by ANZGOG Chair @ProfClareScott AM, FAA FAHMS GAICD and ANZGOG Director, Associate Professor @YolandAntill highlights the growing impact of gynaecological cancers in Australia and the urgent need for greater awareness, investment, and action. Australia has made significant advances in the prevention of cervical cancer, however, progress on other gynaecological cancers is falling behind. Today, more than 26,000 women in Australia are living with a gynaecological cancer diagnosis, with incidence projected to rise by 21% over the next decade. Yet despite this growing burden, gynaecological cancers remain among the most under-recognised and underfunded cancer groups in Australia. More than 55% of gynaecological cancers are classified as rare or low survival, reinforcing the critical role of clinical trials and research in improving outcomes and expanding access to more personalised and effective treatments for those diagnosed with ovarian, uterine, cervical, vulvar, and vaginal cancers. “The future we seek is one where no woman dies prematurely from a gynaecological cancer, and where every woman, regardless of where she lives or her circumstances, has access to the latest, most effective treatments. Through commitment, collaboration, and innovation, this future is within reach.” ANZGOG acknowledges and thanks the researchers, clinicians, community, philanthropic supporters, partners, advocates, and government stakeholders who continue to drive progress for women diagnosed with a gynaecological cancer. Improving outcomes and saving lives depends on sustained collaboration across research, healthcare, policy, and community. Read the full article here: insightplus.mja.com.au/2026/… #GynaecologicalCancer #WomensHealth #CancerResearch #ClinicalTrials #ANZGOG

The Ovarian Cancer Session at #ANZGOG2026ASM was a highlight of this year's meeting, bringing together leading experts to reflect on progress, confront ongoing challenges, and look ahead to the next wave of clinical innovation 🔬 Chaired by Michelle Harrison and Bryony Simcock, the session spanned the full continuum of care, from platinum-resistant disease to follow-up, culminating in a forward-looking panel discussion on future trial priorities: 🧬 @DrKatyMoore - Management of Platinum Resistant Ovarian Cancer 🧬 Nikki Burdett - Managing Ovarian Cancer Post PARPi 🧬 Naven Chetty - TRUST: What Has It Changed for Us and Why? 🧬 Paul Cohen - Getting the MOST Out of Ovarian Cancer Follow-Up A standout moment was @DrKatyMoore's reflection on three new therapies now showing survival benefit in ovarian cancer - a powerful reminder of what this community's persistence and collaboration can achieve for patients. Thank you to @kylie_gorringe for capturing that insight, and to all speakers for their invaluable contributions across a rich and thought-provoking session 👏 #OvarianCancer #AdvancingResearchSavingLives #CancerResearch

ANZGOG's IGNITE trial has been selected for a poster presentation at #ASCO2026 📜 Study Chair, Dr @g_auyeung, will be at the meeting to present. 💬 IGNITE is investigating new treatment options for women with recurrent ovarian cancer whose tumours express high levels of a protein called Cyclin E1. These patients typically have limited treatment options and do not respond well to some of the newer therapies available, including PARP inhibitors. With 2,200 women diagnosed with ovarian cancer in Australia and New Zealand every year and fewer than half surviving beyond five years, research like IGNITE is critical. Having this work recognised on the world's largest oncology stage reflects the importance of finding new options for this underserved patient group. #ANZGOG #CancerResearch #OvarianCancer